» Articles » PMID: 37749037

[Efficacy of Decitabine in Patients with Glucocorticoid-resistant Primary Immune Thrombocytopenia: Factors Influencing Treatment Responses]

Overview
Specialty Hematology
Date 2023 Sep 25
PMID 37749037
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to evaluate the efficacy of decitabine (DAC) and identify factors influencing treatment responses in patients with primary immune thrombocytopenia (ITP) who had failed glucocorticoid therapy. Clinical data of 61 patients with glucocorticoid-resistant ITP who received DAC therapy (5 mg·m(-2)·d(-1)×3 d via intravenous infusion) for at least three cycles with 3-4-week intervals at the Department of Hematology, Qilu Hospital of Shandong University, from November 2015 to June 2021 were analyzed retrospectively. The 61 patients comprised 20 males and 41 females, with a median age of 45 years (range: 15-81 years). Among them, 43 patients were glucocorticoid-dependent (glucocorticoid-dependent group), while 18 patients were glucocorticoid-resistant (glucocorticoid-resistant group). Following DAC treatment, 12 patients (19.67% ) achieved complete response (CR), and 16 patients (26.23% ) exhibited response (R), resulting in an overall response (OR) rate of 45.90% (28/61). Comparison between the OR group (=28) and the non-response (NR) group (=33) revealed significant differences in responses to glucocorticoids (dependent or resistant) and platelet counts before treatment ((2)=8.789, =0.003; =-2.416, =0.016). The glucocorticoid-dependent group showed higher platelet counts than the glucocorticoid-resistant group after the second and third cycles of DAC treatment (=0.032, 0.024). Moreover, the OR rates after the first, second, and third cycles of DAC treatment in the glucocorticoid-dependent group were all higher than those in the glucocorticoid-resistant group (=0.042, =0.012, =0.029). A significant correlation was observed between glucocorticoid dependence and responses to DAC treatment (=9.213, 95% 1.937-43.820, =0.005) . DAC demonstrates definitive efficacy with mild adverse effects in a subset of patients with glucocorticoid-resistant primary ITP. Glucocorticoid dependence and higher platelet counts before treatment are associated with a favorable response to DAC therapy.

References
1.
Zufferey A, Kapur R, Semple J . Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP). J Clin Med. 2017; 6(2). PMC: 5332920. DOI: 10.3390/jcm6020016. View

2.
Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T . Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost. 2006; 4(9):1936-43. DOI: 10.1111/j.1538-7836.2006.02091.x. View

3.
Ni X, Wang L, Wang H, Yu T, Xie J, Li G . Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia. Blood. 2022; 140(26):2818-2834. DOI: 10.1182/blood.2022016029. View

4.
Zhou H, Hou Y, Liu X, Qiu J, Feng Q, Wang Y . Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost. 2015; 113(5):1021-34. DOI: 10.1160/TH14-04-0342. View

5.
Han P, Hou Y, Zhao Y, Liu Y, Yu T, Sun Y . Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood. 2021; 138(8):674-688. PMC: 8394906. DOI: 10.1182/blood.2020008477. View